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Abstract
Background: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to
obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will
eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic
steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in
tumor necrosis factor α (TNF-α) production, lipid peroxidation and oxidative stress.
Methods: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group
(n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol
(n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4
days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given
resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration
and bacterial translocation. Levels of TNF-α in serum, hepatic malondialdehyde (MDA), oxidative stress
(superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical
parameters were measured.
Results: Fat deposition was decreased in the resveratrol group as compared to the steatosis group
(Grade 1 vs Grade 3, P < 0.05). TNF-α and MDA levels were significantly increased in the steatosis group
(TNF-α; 33.4 ± 5.2 vs 26.24 ± 3.47 pg/ml and MDA; 9.08 ± 0.8 vs 3.17 ± 1.45 μM respectively, P < 0.05).
This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and
decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group).
Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of
rats given resveratrol (P < 0.05).
Conclusion: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by
TNF-α inhibition and antioxidant activities.
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Background
Nonalcoholic fatty liver disease (NAFLD) is characterized
by histological changes similar to those seen in subjects
with alcoholic hepatitis but in whom alcohol intake is
absent or poorly significant. Factors promoting NAFLD
development include obesity and diabetes. From 69% to
100% of patients with NAFLD are obese [1]. NAFLD prev-
alence in severe obesity is greater than 30% [2,3]. Because
of all these reasons, it is important to have animal models
that allow us to study the effect of different substances on
NAFLD.
Polyphenols have a variety of biological functions, includ-
ing antioxidant, anti-inflammatory, and anticancer effects
[4]. Resveratrol is a phytoalexin polyphenolic compound
occurring in various plants, including grapes, berries, and
peanuts. Multiple lines of compelling evidence suggest its
beneficial effects on neurological, hepatic, and cardiovas-
cular systems. The potential mechanisms responsible for
its biological activities include downregulation of the
inflammatory response through inhibition of the synthe-
sis and release of pro-inflammatory mediators, modifica-
tion of eicosanoid synthesis, inhibition of Kupffer cells
and adhesion molecules, inhibition of inducible nitric
oxide synthase and cyclooxygenase-2 (COX-2) via its
inhibitory effects on nuclear factor (kappa)B (NF-kB) or
the activator protein-1 (AP-1) (5,6). In our previous stud-
ies, resveratrol was seen to decrease the liver lesions and
transaminase elevations caused by alcohol in mice [7].
Our purpose now was to investigate first whether resvera-
trol decreased hepatic steatosis in an animal model of
steatosis, and second, whether this therapeutic approach
resulted in a decrease in tumor necrosis factor α (TNF-α)
production and oxidative stress.
Methods
Animals and diets
Wistar CRL: Wi (Han) male rats (Charles River) weighing
approximately 225 g were used. All experiments were con-
ducted in accordance with the Guide for the Care and Use
of Laboratory Animals published by the US Public Health
Service. Animals were kept on a regular 12-hour light
period at a controlled temperature (25 ± 2°C). The mod-
ified diet (high carbohydrate-fat free) consisted of carbo-
hydrates (80%, as starch), protein (16%, as casein), and
vitamins and minerals (4%)(PANLAB, Barcelona, Spain).
The standard diet consisted of a balanced diet containing
carbohydrates (51%), protein (16%), vitamins and min-
erals (4%), and lipids (3%). The standard diet contained
2.9 kcal/g, and the modified diet 3.58 kcal/g. The model
was based on the model reported by Delzenne in 1997
[8].
Experimental procedures
Rats were distributed into three groups: control, steatosis
and resveratrol. The control group was given free access to
feed and drink. The control group was fed a standard diet.
The steatosis and resveratrol groups were given free access
to feed and water 4 days per week, and were fasted for the
remaining 3 days (access to water was only allowed). Feed
consisted of a modified diet. During the dietary restriction
cycles, steatosis and resveratrol groups were fed a modi-
fied diet (Figure 1). Rats in the resveratrol group were
given resveratrol 10 mg daily by the oral route through an
orogastric catheter. Resveratrol was diluted in 1 mL of
water. Resveratrol was obtained from SIGMA Chemical,
(Pool, Dorset, UK).
All rats were killed after completing 4 cycles of feeding
and fasting, i.e. 28 days after study start. The timing of kill-
ing was decided based on previous trials in which hepatic
damage was seen to be very high after four weeks in the
steatosis group. Feed taken by the rats and weight of the
animals were controlled at the end of the study. At the end
of the study, all rats were anesthetized using an intraperi-
toneal injection of an overdose (45 mg/kg) of sodium
pentobarbital.
Pathological evaluation
A histological study was performed following a midline
laparotomy to remove the liver. Liver was weighed, and
liver tissue samples taken at the time the rat was killed
were immediately placed in 10% buffered formalin and
subsequently embedded in paraffin. Hepatic index was
obtained by dividing liver weight by rat weight × 100.
Liver sections were stained with hematoxylin and eosin
using standard techniques. Sections were viewed without
knowing the treatment group to which each animal
belonged. Biopsies were classified into four grades
depending on fat accumulation using the Brunt et al [9]
classification, assigning grade 0 when no fat was found in
the liver, grade 1 when fat vacuoles were seen in less than
33% of hepatocytes, grade 2 when 33%–66% of hepato-
cytes were affected by fat vacuoles, and grade 3 when fat
vacuoles where found in more than 66% of hepatocytes.
The deposit of fat was classified in macrovesicular, micro-
vesicular and mixed. Two experienced pathologists
blinded to the experiment evaluated all samples. Agree-
ment between both pathologists was determined.
Biochemical measurements
Laboratory parameters such as ALT, glucose, and albumin
were measured using an automatic analyzer (Roche/
Hitachi Modular Analytics, Roche Diagnostics, Man-
nheim, Germany) at 37°C.BMC Gastroenterology 2008, 8:40 http://www.biomedcentral.com/1471-230X/8/40
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Serum TNF-α levels was measured using ELISA kits (R&D
Systems, Boston, MA-Catalog Number RTA00). TNF-α
levels was expressed in pg/mL.
Lipid peroxidation
Malondialdehyde (MDA) was measurement in hepatic tis-
sue. For hepatic malondialdehyde (MDA) determination,
weigh 25 mg of tissue and add 250 μl of RIPA buffer with
protease inhibitors. Sonicate for 15 seconds at 40 V over
ice and centrifuge at 1.600 × g for 10 minutes at 4°C. We
use the supernatant for analysis. MDA was quantified
using the thiobarbituric acid reaction as described by
Ohkawa [10]. MDA levels were measured using Cayman's
TBARS Assay Kit. MDA levels were expressed in μM.
Oxidative stress
Superoxide dismutase, catalase, glutathione peroxidase,
and nitric oxide synthase levels as oxidant/antioxidant
biochemical parameters were measurement in hepatic tis-
sue. Levels were quantified using Cayman's (Cayman
Chemical Company, Ann Arbor – Michigan, USA) assay
kit following the instructions of the manufacter.
Bacterial translocation determination
Samples of mesenteric lymph nodes and portal and
peripheral blood when available were collected under
sterile conditions before rat death and cultured in MacCo-
nkey agar (Oxoid), Columbia sheep blood (Oxoid), and
Esculin-Bile-Azide agar (Merck), and incubated at 37°C
for 48 h. Bacterial translocation was defined as a positive
culture of mesenteric lymph nodes. Systemic infections
were defined as a positive culture of any of the remaining
biological samples.
Statistical analysis
Data are expressed as the mean ± SD statiscal analysis was
performed with non-parametric Mann-Whitney test.
Standard calculations were performed using SPSS version
16.0. Results were considered statistically significant at P
< 0.05.
Results
Rat weight significantly increased in the control group
(221 ± 10 g to 355 ± 16 g), remained similar in the group
with fatty liver disease (222 ± 12 g to 226 ± 14 g), and
decreased in the resveratrol group (218 ± 9 g to 201 ± 11
g). Hepatic index was 4.47 ± 0.63, 4.38 ± 0.34, and 3.9 ±
0.31 in the steatosis, resveratrol, and control groups
respectively.
Histological evaluation
No fatty infiltration was seen in the control group (Figure
2). Mean fatty infiltration in the steatosis group was 3
(Table 1). Fat deposit in the steatosis group was classified
as macrovesicular. Mean fatty infiltration in the resvera-
trol group was 1, and fat deposit was mixed. Fatty infiltra-
NAFLD model used in the study Figure 1
NAFLD model used in the study.
Model of steatosis 
Standard diet 
Control   
28 days
Resveratrol 
  Steatosis
4d 3d 4d 3d 4d 3d 4d
4d 4d 4d 4d 3d 3d 3d
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tion in the resveratrol group was significantly lower than
in the steatosis group (P < 0.05). Inter-observer agreement
was 0.84 and intra-observer agreement was 0.79.
Laboratory findings
ALT levels were 40 ± 11 IU/L in the control group, 34 ± 9
IU/L in the steatosis group, and 34 ± 11 IU/L in the resver-
atrol group (P < 0.05 between control group vs steatosis
and resveratrol groups). Glucose levels were 230 ± 45 mg/
dl in the control group, 162 ± 25 mg/dl in the steatosis
group, and 145 ± 33 mg/dl in the resveratrol group. Statis-
tically significant differences in glucose levels were seen
between the control and steatosis groups and the resvera-
trol group (P < 0.05 between control group vs steatosis
and resveratrol groups). Albumin levels were 38.1 ± 2.3 g/
dl in the control group, 40.54 ± 1.87 g/dl in the steatosis
group, and 41.1 ± 2.9 g/dl in the resveratrol group (P <
0.05 between control group vs steatosis and resveratrol
groups).
TNF-α and lipid peroxidation (MDA)
Figure 3 shows that TNF-α levels were increased in the
steatosis group as compared to the other two groups (P <
0.05). MDA was significantly elevated in the steatosis
group as compared to the control group (μM). MDA liver
levels were lower in the resveratrol group than in the stea-
tosis group (P < 0,001).
Oxidative stress
The data in table 2 demostrate that resveratrol administra-
tion significantly decreased the effects of the stress oxida-
tive in the hepatic tissue.
Bacterial translocation and systemic infections
Cultures of samples of portal blood, peripheral blood,
and perihepatic lymph nodes were negative in all three
groups tested.
Discussion
NAFLD represents a wide spectrum of disorders, the hall-
mark of which is hepatic steatosis. NAFLD was considered
a benign condition, but is now increasingly recognized as
a major cause of liver-related morbidity and mortality.
Insulin resistance is the basis for accumulation of free fatty
acids and triglyceride storage in hepatocytes or steatosis.
Oxidative stress from steatotic hepatocytes leads to lipid
peroxidation, impaired mitochondrial and peroxisomal
oxidation of fatty acids, and cytokine release [11]. Endo-
toxins and endotoxin-inducible cytokines, particularly
TNF-α, are required for the pathogenesis of NAFLD in
experimental animals. Therefore the TNF-α plays an
important role in NAFLD [12,13].
In our study, hepatic steatosis was significantly decreased
in rats treated with resveratrol. This effect was associated
to a decreased TNF-α production. Different studies have
shown that resveratrol decreases TNF-α production. We
therefore think that the decreased liver damage in a model
of liver steatosis could be related to its anti-TNF-α effect.
Other studies [14-16] have shown a relationship between
NAFLD and TNF-α levels. Our study shows that TNF-α
levels were increased in both the steatosis and resveratrol
groups as compared to the control group, suggesting that
TNF-α is an important factor in liver damage occurring in
NAFLD. However, TNF-α levels were lower in the resvera-
Table 1: Grades of fatty infiltration in rats and groups.
Group Rats (n°) Steatosis grades
0 123
C o n t r o l 1 2 1 2---
Steatosis 12 - - 2 10
Resveratrol 12 - 10 2 -
Histological study in the different groups (control, steatosis, and resveratrol) Figure 2
Histological study in the different groups (control, steatosis, and resveratrol). Thus, the control group is shown to 
have no fat vacuoles. A great number of vacuoles were seen in the steatosis group, while the resveratrol group had much less 
vacuoles of a lower size. Hematoxylin and eosin staining of liver tissue × 40.
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TNF-α and MDA levels Figure 3
TNF-α and MDA levels. A. TNF-α levels in differents groups (pg/mL). TNF-α levels were lower in the resveratrol groups as 
compared to the control and steatosis groups. B. Levels of MDA in differents groups (μM). MDA levels were lower in the res-
veratrol groups as compared to the steatosis group (*P < 0.05).
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trol group than in the steatosis group. We therefore think
that TNF-α is an important factor for development of this
condition. In agreement with other authors [17-19], we
did not consider administration of anti-TNF-α or use of
another group given repeated TNF-α doses because ade-
quate evidence was already available. Infliximab (anti-
TNF-α) reverses the steatosis and the expression of the
proinflammatory markers (TNF-α, IL6, IL-1B) and
improves insulin signal trasduction in a model of steatosis
in rats [20]. The presence of a control group (reference
group) allows to compare the effects of the modified diet
(high carbohydrate-fat free) on the liver (steatosis group)
and the effect of the resveratrol (resveratrol group).
Bacterial translocation from the intestinal lumen to
mesenteric lymph nodes is considered to be one of the
main events in the pathogenesis of spontaneous bacterial
peritonitis and other infections in cirrhosis. TNF-α is
involved in the occurrence of bacterial translocation in
rats with cirrhosis [21]. We therefore considered whether
bacterial translocation acting as a stimulus for TNF-α pro-
duction occurred in our model. Cultures of samples of
portal blood, peripheral blood, and perihepatic lymph
nodes were negative in all three groups tested, which rules
out this mechanism as responsible for TNF-α elevation.
There are many models of NAFLD liver injuries in animals
[22,23]. In rats, cycles of feeding and fasting with hyper-
tonic high calorie diets have been seen to induce fatty liver
[8]. In this study, we used feeding and fasting cycles with
a modified diet because it is a fast, easy procedure that
results in pathological changes similar to those occurring
in humans. In our model the deposit of fatty acids and
triglyceride storage in hepatocytes is produced by insulin
resistance [8,11]. Insulin resistance is the basis for accu-
mulation of free fatty acids and triglyceride storage in
hepatocytes, and represents the "first hit" in the pathogen-
esis of NAFLD [11]. Body mass significantly decreased
with the high carbohydrate-fat free diet and dietary restric-
tion. This may be due to a metabolic imbalance of carbo-
hydrate, protein, and fat. However, hepatic index was
higher in the group with steatosis as compared to the res-
veratrol and control groups. Such higher hepatic index
occurred despite the increased rat weight in the steatosis
group, which means that resveratrol acts by decreasing fat
accumulation in the liver and fat weight, and therefore
decreases hepatic index.
ALT is a relatively liver-specific aminotransferase. Eleva-
tion of ALT activity in serum is the result of leakage from
damaged cells and therefore reflects hepatocyte damage.
Elevated transaminase levels correlated strongly with
NAFLD [2]. ALT levels were significantly lower in the res-
veratrol group as compared to the control group (34 IU/L
versus 40 IU/L) and similar to steatosis group levels. In the
group treated with resveratrol, lower glucose levels and
higher serum albumin levels as compared to untreated
rats were also found. Studies have reported increases in
serum TNF-α levels in humans with insulin resistance
[24]. Hyperglycemia and insulin resistance are associated
to the presence of NAFLD [2,25]. Changes in plasma lev-
els of markers predicting for the onset of diabetes occurred
with a high carbohydrate-fat free diet [25]. Glucose levels
were decreased in the resveratrol group [26], as occurred
in our study. Other studies have also noted that resvera-
trol improved insulin sensitivity, lowered plasma glucose,
and increased mitochondrial capacity in obese mice [27].
Insulin resistance was not analyzed in our study.
High hepatic MDA levels were found in the steatosis
group, in agreement with other studies [28]. Resveratrol
improved MDA levels. Oxidative stress is believed to play
an important role in pathogenesis of NAFLD. It is likely to
be involved in disease progression from steatosis to stea-
tohepatitis and potentially cirrhosis. It has been shown
that chronic oxidative stress, generated through oxidation
of cytotoxic free fatty acids, may lead to cytokine upregu-
lation and depletion of hepatic antioxidant levels [29,30].
In addition, enhanced lipid peroxidation leads to the gen-
eration of by-products, such as MDA, which have been
shown to further stimulate cytokine production. They are
involved in hepatic stellate cell activation, fibrogenesis,
and enhanced extracellular matrix protein deposition
[28]. Resveratrol caused increased of hepatic antioxidant
levels as superoxide dismutase, glutathione peroxidase
and catalase and decreased nitric oxide synthase in the
liver.
Fatty acid oxidation is an important source of reactive oxy-
gen species in fatty livers. Some consequences of increased
Table 2: Changes of superoxide dismutase, catalase, glutation peroxidasa and nitric oxide synthase in each group.
Control Steatosis Resveratrol
Superoxide dismutase (U/ml) 2.74 ± 2.08 1.15 ± 2.1 3.1 ± 3.2*
Catalase (nmol/min/ml) 3807 ± 315 284 ± 26 713 ± 50*
Glutathione peroxidase (nmol/min/ml) 449 ± 27 6.5 ± 3 406 ± 25*
Nitric oxide synthase (uM) 1.9 ± 0.6 9.17 ± 0.9 4.19 ± 0.7*
*P < 0.05 vs steatosis groupBMC Gastroenterology 2008, 8:40 http://www.biomedcentral.com/1471-230X/8/40
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reactive oxygen species levels include an impaired protein
stability, membrane destruction via lipid peroxidation,
and release of proinflammatory cytokines (increased TNF-
α levels) [31]. Reactive oxygen species may attack polyun-
satured fatty acids and initiate lipid peroxidation within
the cell, which results in MDA formation. Oxidants may
not only act as toxic substances, but also as second mes-
sengers (activation of transcription factor NF-kB) [32].
Resveratrol increases insulin sensitivity and insulin-like
growth factor-1 levels (IGF-1) [28]. Resveratrol would also
act by decreasing lipid peroxidation and reactive oxygen
species release, thereby decreasing inflammatory response
and liver lesions [33,34]
Recently, researches suggest that other mechanisms the
resveratrol improve in NAFLD are by the activation of
AMP-activated protein kinase and the activation of SIRT1
[35-37].
Conclusion
In summary, our study shows that resveratrol decreases
liver steatosis in rats and that its effect is mediated, at least
partly, by TNF-α and antioxidant activities. In our model,
bacterial translocation was not responsible for TNF-α ele-
vation. Further studies are warranted to determine
whether resveratrol decreases or prevents liver steatosis.
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